MedTrace Logo

FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

NCT01688336 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-10-06

Study results available
· View outcomes & findings →

Summary

This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic cancer.

Conditions

Interventions

DRUG

FOLFIRINOX

FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order: * Oxaliplatin (85 mg/m2) * Leucovorin (400mg/ m2) * Irinotecan (180 mg/m2) * 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Autumn J McRee, MD · University of North Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-08-22
Completion
2016-11-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01688336 on ClinicalTrials.gov